Literature DB >> 29602073

Role of IL-1β, IL-6 and TNF-α cytokines and TNF-α promoter variability in Plasmodium vivax infection during pregnancy in endemic population of Jharkhand, India.

Krishn Pratap Singh1, Shayan Shakeel2, Namrata Naskar3, Aakanksha Bharti4, Asha Kaul5, Shadab Anwar6, Shweta Kumari2, Amod Kumar2, Jiv Kant Singh7, Nutan Kumari8, Birendra Kumar Gupta2, Purwa Manna9, Vishwaprakash Roy9, Sneh Lata10, Om P Singh5, Manoranjan Prasad Sinha11, Ajay Kumar Sharma12, Mohammad Sohail13.   

Abstract

BACKGROUND: The combinatorial effects of Plasmodium infection, perturbation of inflammatory responses and the dichotomic role of TNF promoter polymorphism has potential clinical and physiological relevance during pregnancy. OBJECTIVE AND METHODS: This coordinated orchestration instigated us to investigate the circulating level of inflammatory cytokines (IL-1β, TNF-α and IL-6) employing ELISA in a stratified group of samples and the plausible genetic association of TNF-α -308 G/A using PCR-RFLP/sequencing during Plasmodium vivax infection in pregnancy.
RESULTS: We observed significantly elevated concentrations of IL-1β were observed, followed by IL-6 and TNF-α in women with malaria (WWM) and in malaria in pregnancy (MIP). Further, elevated IL-1β, followed by TNF-α and IL-6 were detected in the non-infected pregnancy group. The differential dynamics of inflammatory cytokine concentration during each trimester of pregnancy with and without P. vivax infection were detected. For the first time, a high level of IL-6 was observed in the first trimester of MIP and high IL-1β in healthy pregnancies. In the second trimester, however, we observed a high level of IL-1β in the MIP group compared to a sustained high level of IL-1β in the healthy pregnancy group. In the third trimester, high IL-1β was sustained in the MIP group and healthy pregnancies acquired a high TNF-α level. The genotypic distribution for the TNF-α promoter -308 G/A position was observed to be nonsignificant and mildly associated during MIP (OR = 1.4) and in WWM (OR = 1.2). Moreover, based on genotypic distribution, we observed a well-correlated and significantly elevated TNF-α concentration in the mutant homozygote genotype (AA; p = 0.001) followed by heterozygotes (GA; p = 0.0001) and ancestral genotypes (GG; p = 0.0001) in both MIP and WWM subjects.
CONCLUSION: The observation of elevated IL-1β and IL-6 in MIP and TNF-α in WWM may be regarded as a prognostic inflammatory marker of infection and pregnancy. Most particularly, the TNF-α concentration and its polymorphic variability in the promoter region may indicate genetic susceptibility and mildly influence the risk for P. vivax infection during pregnancy and in women with malaria.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Inflammatory cytokines; Jharkhand; MIP; Promoter Polymorphism; Vivax malaria; phism

Mesh:

Substances:

Year:  2018        PMID: 29602073     DOI: 10.1016/j.molimm.2018.03.019

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  3 in total

1.  Prevalence of Pregnancy Associated Malaria in India.

Authors:  Khushi Jain; Palak Gupta; Ashutosh Balodhi; Farah Deeba; Nasir Salam
Journal:  Front Glob Womens Health       Date:  2022-05-26

2.  Cytokine signatures of Plasmodium vivax infection during pregnancy and delivery outcomes.

Authors:  Carlota Dobaño; Azucena Bardají; Myriam Arévalo-Herrera; Flor E Martínez-Espinosa; Camila Bôtto-Menezes; Norma Padilla; Michela Menegon; Swati Kochar; Sanjay Kumar Kochar; Holger Unger; Maria Ome-Kaius; Anna Rosanas-Urgell; Adriana Malheiros; Maria Eugenia Castellanos; Dhiraj Hans; Meghna Desai; Aina Casellas; Chetan E Chitnis; Carlo Severini; Ivo Mueller; Stephen Rogerson; Clara Menéndez; Pilar Requena
Journal:  PLoS Negl Trop Dis       Date:  2020-05-04

3.  Testing an infection model to explain excess risk of preterm birth with long-term iron supplementation in a malaria endemic area.

Authors:  Bernard Brabin; Halidou Tinto; Stephen A Roberts
Journal:  Malar J       Date:  2019-11-26       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.